Long-term Follow-up of the MERIT Trial Reveals Durable Nivolumab Efficacy
Immunotherapy as second- and third-line treatment is effective in pre-treated malignant pleural mesothelioma
Oncologists Are More Prepared to Face Pandemic-related Challenges
Presentations at ESMO Virtual Congress 2020 gave insights into the impact of COVID-19 on cancer management, cancer research and the healthcare professionals involved, which can help to prepare for future crises.
How to Bring Innovation to Patients Diagnosed with Rare Cancers?
Study design still seems to be a major limitation to translate promising approaches in rare cancers, as negative trials presented at the ESMO Virtual Congress 2020 show.
Early Promise With Novel Treatments in Advanced Ewing Sarcoma
Encouraging data from phase I and II studies in pre-treated adult patients but not in children where prognosis is poor.
Growing Evidence for the Benefit of Targeting Molecular Alterations in Rare Head and Neck Cancer
Findings from early clinical trials at the ESMO Virtual Congress 2020 are encouraging for the use of precision medicine in adenoid cystic carcinoma and salivary gland carcinoma
Lenvatinib Plus Pembrolizumab Show Promise in Melanoma After Progression on Checkpoint Inhibitors
In the LEAP-004 study presented at the ESMO Virtual Congress 2020, ORR is encouraging but survival results are difficult to interpret.
Ovarian Cancer: First-line Dose-dense Chemotherapy is Not Superior to Standard 3-weekly Chemotherapy
ICON8 trial final analysis confirms results of the previously published progression-free survival analysis
Men and Women Benefit Differently from Immunotherapy
Understanding the impact of the patients’ sex on clinical outcomes to treatment with immunotherapy might add another piece to the puzzle of the most effective way to use checkpoint inhibitors.
Pembrolizumab Could Become a New Standard Option for Treatment of Kaposi Sarcoma
Encouraging early data suggests PD-1 blockade is also effective in other advanced non-melanoma skin cancers such as advanced basal cell carcinoma.
Are Higher Prices of Anticancer Medicines Reflected in Better Outcomes for Patients?
Studies presented at the ESMO Virtual Congress 2020 report high expenditure in the research and development process and discrepancies in costs of therapies among countries